Phio Pharmaceuticals(PHIO) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Phio Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update MARLBOROUGH, Mass., August 14, 2024—Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today reported its financial results for the quarter ended June 30, 2024 and provided a business update. Recent Corporate Updates · The Phase 1b clinical ...